2. TEXT ABSTRACT AND KEYWORDS
Background and Aims People with monogenic familial hypercholesterolaemia (FH) are at an increased risk of premature coronary heart disease and death. Currently there is no population screening strategy for FH, and most carriers are identified late in life, delaying timely and cost-effective interventions. The aim was to derive an algorithm to improve detection of people with monogenic FH.
Methods A penalised (LASSO) logistic regression model was used to identify predictors that most accurately identified people with a higher probability of FH in 139,779 unrelated participants of the UK Biobank, including 488 FH carriers. Candidate predictors included information on medical and family history, anthropometric measures, blood biomarkers, and an LDL-C polygenic score (PGS). Model derivation and evaluation was performed using a random split of 80% training and 20% testing data.
Results A 14-variable algorithm for FH was derived, where the top five variables included triglyceride, LDL-C, and apolipoprotein A1 concentrations, self-reported statin use, and an LDL-C PGS. Model evaluation in the test data resulted in an area under the curve (AUC) of 0.77 (95% CI: 0.71; 0.83), and appropriate calibration (calibration-in-the-large: -0.07 (95% CI: -0.28; 0.13); calibration slope: 1.02 (95% CI: 0.85; 1.19)). Employing this model to prioritise people with suspected monogenic FH is anticipated to reduce the number of people requiring sequencing by 88% compared to a population-wide sequencing screen, and by 18% compared to prioritisation based on LDL-C and statin use.
Conclusions The detection of individuals with monogenic FH can be improved with the inclusion of additional non-genetic variables and a PGS for LDL-C.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JG is supported by the BHF studentship FS/17/70/33482. AFS is supported by the BHF grant PG/18/5033837 and the UCL BHF Research Accelerator AA/18/6/34223. CF and AFS received additional support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. ADH is an NIHR Senior Investigator. SH and MF were supported by a grant from the British Heart Foundation (BHF grant PG 08/008) and by funding from the Department of Health's NIHR Biomedical Research Centers funding scheme.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval. This approval means that researchers do not require separate ethical clearance and can operate under the RTB approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.